Carcinogenesis Advance Access originally published online on May 5, 2005
Carcinogenesis 2005 26(9):1536-1541; doi:10.1093/carcin/bgi115
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Carcinogenesis vol.26 no.9 © Oxford University Press 2005; all rights reserved.
Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma
1 Department of Surgery and 2 Department of Pathology, Division of Molecular Pathology and Molecular Genetics, Dalhousie University, Halifax, Nova Scotia, Canada and 3 Department of Public Health Sciences, University of Alberta, Edmonton, Alberta, Canada
* To whom correspondence should be addressed Email: alan.casson{at}dal.ca
To test the hypothesis that aberrations of DNA repair contribute to susceptibility for the progression of gastroesophageal reflux disease (GERD) into Barrett esophagus (BE) and esophageal adenocarcinoma (EADC), we studied the frequency of polymorphisms of selected DNA repair genes in patients with GERD (n = 126), BE (n = 125) and EADC (n = 56) enrolled in a 2-year prospective case–control study. Controls comprised 95 strictly asymptomatic healthy individuals. Using genomic DNA extracted from blood samples, we identified wild-type and polymorphic variants of XPD (Arg156Arg and Lys751Gln), XRCC1 (Arg194Trp and Arg399Gln) and XRCC3 (Thr241Met), and the poly (AT) insertion/deletion of XPC (PAT). Allelic frequencies were compared between cases and controls using logistic regression to calculate age, gender, smoking and alcohol-adjusted odds ratios (OR) and 95% confidence intervals (CI). Patients with EADC demonstrated a significantly higher frequency of the XPC PAT homozygous variant genotype compared with asymptomatic controls (OR = 3.82; 95% CI = 1.05–13.93). Significantly reduced frequencies were seen for the XPD Lys751Gln homozygous variant genotype in patients with EADC (OR = 0.24; 95% CI = 0.07–0.88), and for the XRCC1 Arg399Gln homozygous variant genotype in patients with BE (OR = 0.38; 95% CI = 0.12–0.64) and GERD (OR = 0.29; 95% CI = 0.12–0.66). We conclude that the malignant phenotype probably results from a summation of polymorphic nucleotide excision repair genes showing opposing effects (an increased risk of XPC versus a protective effect of XPD). The protective effect of the homozygous variant of XRCC1 Arg399Gln for GERD and BE suggests that base excision repair alterations may occur early in progression to EADC, likely in response to GERD-induced endogenous oxidative or inflammatory DNA damage. As GERD and BE are highly prevalent in the general population, this protective effect may well explain why only a fraction of individuals with GERD and BE progress into invasive EADC.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Hopkins, D. W. Cescon, D. Tse, P. Bradbury, W. Xu, C. Ma, P. Wheatley-Price, J. Waldron, D. Goldstein, F. Meyer, et al. Genetic Polymorphisms and Head and Neck Cancer Outcomes: A Review Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 490 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Ferguson, C. P. Wild, L. A. Anderson, S. J. Murphy, B. T. Johnston, L. J. Murray, R.G. P. Watson, J. McGuigan, J. V. Reynolds, and L. J. Hardie No Association between hOGG1, XRCC1, and XPD Polymorphisms and Risk of Reflux Esophagitis, Barrett's Esophagus, or Esophageal Adenocarcinoma: Results from the Factors Influencing the Barrett's Adenocarcinoma Relationship Case-Control Study Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 736 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lin, G. E. Swan, P. G. Shields, N. L. Benowitz, J. Gu, C. I. Amos, M. de Andrade, M. R. Spitz, and X. Wu Mutagen Sensitivity and Genetic Variants in Nucleotide Excision Repair Pathway: Genotype-Phenotype Correlation Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2065 - 2071. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Liu, W. Zhou, B. Y. Yeap, L. Su, J. C. Wain, J. M. Poneros, N. S. Nishioka, T. J. Lynch, and D. C. Christiani XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk Carcinogenesis, June 1, 2007; 28(6): 1254 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Murphy, A. E. Hughes, C. C. Patterson, L. A. Anderson, R.G.P. Watson, B. T. Johnston, H. Comber, J. McGuigan, J. V. Reynolds, and L. J. Murray A population-based association study of SNPs of GSTP1, MnSOD, GPX2 and Barrett's esophagus and esophageal adenocarcinoma Carcinogenesis, June 1, 2007; 28(6): 1323 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Li, Z. Hu, Z. Liu, L.-E Wang, S. S. Strom, J. E. Gershenwald, J. E. Lee, M. I. Ross, P. F. Mansfield, J. N. Cormier, et al. Polymorphisms in the DNA Repair Genes XPC, XPD, and XPG and Risk of Cutaneous Melanoma: a Case-Control Analysis Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2526 - 2532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R C Fitzgerald Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut, December 1, 2006; 55(12): 1810 - 1820. [Full Text] [PDF]
|
|
|
|
|
|
D. L. Chao, C. C. Maley, X. Wu, D. C. Farrow, P. C. Galipeau, C. A. Sanchez, T. G. Paulson, P. S. Rabinovitch, B. J. Reid, M. R. Spitz, et al. Mutagen Sensitivity and Neoplastic Progression in Patients with Barrett's Esophagus: A Prospective Analysis. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1935 - 1940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Ye, R. Kumar, G. Bacova, J. Lagergren, K. Hemminki, and O. Nyren The XPD 751Gln allele is associated with an increased risk for esophageal adenocarcinoma: a population-based case-control study in Sweden Carcinogenesis, September 1, 2006; 27(9): 1835 - 1841. [Abstract] [Full Text] [PDF]
|
|